ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Cell > PD-L1 > SCRAJ-STT075

Raji/Human PD-L1 Stable Cell Line Development Service

  1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
  2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
  3. Comprehensive application data to support assay development and validation
  4. Full tracible record, stringent quality control and validated cell passage stability
  5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
  6. Global commercial license assistance whenever regulatory filing is required
  • Description
    The Raji/Human PD-L1 Stable Cell Line was engineered to express full length human PD-L1 (Gene ID: 29126, used to mimic cancer target cells. When co-cultured with human PD-1 Reporter Cell, the PD-1/PD-L1 interaction inhibits TCR signaling and NFAT-mediated luminescence. Blocking the PD-1/PD-L1 interaction by either anti-PD-1 or anti-PD-L1 antibodies releases the inhibitory signal and results in TCR activation and NFAT-mediated luminescence.
  • Application

    Useful for cell-based PD-L1 binding assay

    Useful as PD-L1-expressing target cells in reporter gene assay

     PD-L1 Assay Principles

  • Growth Properties
    Suspension
  • Selection Marker
    Puromycin (2 μg/mL)
  • Culture Medium
    RPMI-1640 + 10% FBS
  • Freeze Medium
    Serum-free cell cryopreservation medium
  • Quantity
    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.
Receptor Assay
 PD-L1 FACS

Expression analysis of human PD-L1 on Raji/Human PD-L1 Stable Cell by FACS.
Raji/Human PD-L1 Stable Cell Line or negative control cell were stained with PE-labeled anti-human PD-L1 antibody.

Application
 PD-L1 APPLICATION

Blocking activity of anti-human PD-1 antibody (RLU).
This Raji/Human PD-L1 Stable Cell Line was incubated with serial dilutions of antibodies in the presence of reporter cells expressing human PD-1. The EC50 of anti-human PD-1 antibody was approximately 1.189 μg/mL.

 PD-L1 APPLICATION

Blocking activity of anti-human PD-1 antibody (FOLD).
This Raji/Human PD-L1 Stable Cell Line was incubated with serial dilutions of antibodies in the presence of reporter cells expressing human PD-1. The max induction fold was approximately 22.47.

Please contact us if you are interested in related cell pool service.

  • Background
    Programmed cell death 1 ligand 1 (PDL1) is also known as B7-H, B7H1, MGC142294, MGC142296, PD-L1, PDCD1L1 and PDCD1LG1,which is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses.PDL1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. This protein is broadly expressed in the majority of peripheral tissues as well as hematopoietic cells. Interaction between PDL1 and its receptors belonging to the CD28 family of molecules provide both stimulatory and inhibitory signals in regulating T cell activation and tolerance. PDL1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression.
  • Limited Use&License Disclosure
    1. This cell line is provided for research use only. It is neither intended for any animal or human therapeutic use nor for any direct human in vivo use. You are restricted to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    2. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    3. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    4. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.
  • Clinical and Translational Updates

コメント (0)


ETD of in-stock products: 4 business days

価格(JPY) : 980,000

プロモーション&展示



医薬品開発状況

  • Number of Launched Drugs:7 Details
  • Number of Drugs in Clinical Trials:156 Details
  • Latest Research Phase:Phase 2 Clinical

データシート&ドキュメンテーション

関連製品一覧

新製品

お問い合わせ&コメント

This web search service is supported by Google Inc.

totopphone